GIANT BIOGENE HOLDING CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.9 HKD | +1.15% |
|
+8.96% | +48.60% |
| Apr. 30 | Giant Biogene’s Profit Up 47% in 2023 | MT |
| Mar. 26 | Giant Biogene to Pay Special 0.45 Yuan per Share Dividend | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With a 2024 P/E ratio at 26.63 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Sector: Personal Products
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +48.60% | 6.53B | - | ||
| +12.65% | 390B | C- | ||
| +11.63% | 132B | B- | ||
| +17.26% | 76.69B | A+ | ||
| -12.71% | 65.88B | A- | ||
| -11.43% | 46.44B | B+ | ||
| -5.02% | 39.15B | - | ||
| +7.04% | 34.72B | B- | ||
| +11.04% | 17.89B | A- | ||
| +17.65% | 16.55B | B |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 2367 Stock
- Ratings Giant Biogene Holding Co., Ltd.